Brought to you by 
Retrophin sells pediatric disease priority review voucher to Sanofi for $245mm
21 Sep 2020
Executive Summary
Retrophin Inc. sold its rare pediatric disease priority review voucher (PRV) to Sanofi for $245mm. Sanofi paid $150mm up front, and will make two equal payments of $47.5mm in 2016 and 2017.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Retrophin sells pediatric disease priority review voucher to Sanofi for $245mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice